




**Adverse events among cancer patients treated with a combination of nivolumab and ipilimumab as compared to nivolumab monotherapy: A systematic review and meta-analysis**

**Supplemental Digital Content**


**Appendix A: Risk of Bias graph**

Amaria 2018	?	?	?	?	?	?	?
D'Angelo 2018	?	+	-	?	+	+	?
Gettlinger 2021	+	+	-	?	+	+	+
Hellmann 2019	?	?	-	+	+	+	?
Janjigian 2018	?	?	-	+	+	+	?
Larkin 2019	+	+	+	+	+	+	+
Long 2019	+	?	-	-	+	+	?
Omuro 2018	?	?	-	+	+	+	?
Ready 2019	+	?	-	+	+	+	?
Scherpervel 2019	+	-	-	?	+	+	+
Schoenfeld 2020	?	?	-	-	+	+	?
Sharma 2020	+	?	-	+	+	+	?
Zamarin 2020	+	?	-	-	+	+	?
Zimmer 2020	+	+	+	+	+	+	+
	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias

 Low risk of bias
  High risk of bias
  Unclear risk of bias


**Figure 1: Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**

## Appendix B: Analysis of Publication bias



**Figure 2A: Funnel plot for any grade TRAEs**

The funnel plot for Figure 2A shows no evidence of publication bias. Egger's test for a regression intercept gave a p-value of 0.553, indicating no evidence of publication bias.



**Figure 2B: Funnel plot for grade 3 or 4 TRAEs**

The funnel plot for Figure 2B shows no evidence of publication bias. Egger's test for a regression intercept gave a p-value of 0.1965, indicating no evidence of publication bias.